Skip to the main content

Review article

https://doi.org/10.15836/ccar2024.177

Interference of Atrial Fibrillation with Implantable Cardioverter Defibrillator Therapy in Patients with Heart Failure and Reduced Ejection Fraction

Dubravko Petrač ; Croatia Poliklinika, Zagreb, Hrvatska
Vjekoslav Radeljić ; Klinički bolnički centar Sestre milosrdnice, Zagreb, Hrvatska
Diana Delić-Brkljačić ; Klinički bolnički centar Sestre milosrdnice, Zagreb, Hrvatska


Full text: croatian pdf 1.377 Kb

page 177-185

downloads: 147

cite

Full text: english pdf 1.377 Kb

page 177-185

downloads: 107

cite

Download JATS file


Abstract

SUMMARY
Implantable cardioverter defibrillators (ICD) are an important therapeutic option in reducing mortality due to ventricular arrhythmias in patients with heart failure with reduced ejection fraction. Atrial fibrillation (AF) is often present in these patients and may interfere with ICD therapy by inducing inappropriate and appropriate shocks. This issue is important because both types of shock increase mortality in patients with ICD. The strategies to minimize the rate of ICD shocks induced by AF include the optimization of ICD programming, pharmacological therapy for rate or rhythm control, and ablation of AF or atrioventricular junction ablation. In this review, we describe the interference of AF with ICD therapy, examine the impact of this interference on survival, and discuss the strategies for its reduction.

Keywords

interference; atrial fibrillation; implantable cardioverter defibrillator

Hrčak ID:

314500

URI

https://hrcak.srce.hr/314500

Publication date:

8.2.2024.

Article data in other languages: croatian

Visits: 747 *




Introduction

Implantable cardioverter defibrillators (ICD) are a well-established and effective therapy for patients with heart failure with reduced ejection fraction (HFrEF) who survived sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), or those who are exposed to an increased risk of these arrhythmias. (1) With regard to poor left ventricular systolic function, AF is often present in patients with ICD, with a prevalence from 17% to 36% at time of implantation in clinical practice. (2,3) Except for the negative effect on survival, (4,5) AF may interfere with ICD therapy and limits its clinical usefulness by inducing inappropriate and appropriate shocks. This issue is important because ICD shocks are painful, cause psychological disturbances, and may induce ventricular pro-arrhythmia and even death. (6-9) The aim of this review was to explore the possible interference mechanisms of AF with ICD therapy, examine the impact of this interference on survival, and discuss the treatment options available for its reduction.

Mechanisms of atrial fibrillation interference with implantable cardioverter-defibrillator therapy

ICDs are an important therapeutic option in reducing mortality due to ventricular arrhythmias in patients with HFrEF. (10) The primary goal of ICD therapy is to detect and stop the life-threatening ventricular arrhythmia by delivering electrical shock and thus prevent a sudden cardiac death. In that context, ICD shocks delivered for VT/VF are considered appropriate because they save lives. (11) In contrast, ICD shocks delivered for the non-ventricular arrhythmias, like AF, atrial flutter (AFL), supraventricular tachycardia (SVT), atrial tachycardia (AT), sinus tachycardia (ST), or non-arrhythmic events, like electromagnetic interference, myopotentials, and device malfunction or oversensing, are unnecessary and are considered inappropriate. (12)

AF may interfere with ICD therapy in two ways. The first way is more common, and occurs when the fast ventricular rate of AF with relatively regular R-R intervals reaches a device’s programmed detection zone for VT/VF, is misclassified as ventricular arrhythmia, and induces the delivery of inappropriate shock (Figure 1). According to data from randomized clinical trials, a history of AF was found in 9% to 24% of patients with ICD (Table 1), more often in patients with non-ischemic than in those with ischemic cardiomyopathy. (13-19) On the other hand, the incidence of new-onset AF lasting at least 24 hours per day was 6.3% and 7.1% in single chamber and doubled chamber patients with ICD, respectively. (20) Therefore, it is not surprising that AF/AFL was the most common reason for an inappropriate ICD shock, followed by ST/SVT and non-arrhythmic events. (21,22) In earlier randomized clinical trials, (15,21,23,24) the rate of inappropriate ICD shocks ranged from 15% to 21% over 20 to 45.5 months of follow-up (Table 1). Later, thanks to device programming adjustment and enhanced algorithm discrimination of arrhythmias, the rate of inappropriate shocks decreased, (18,19,25) but even with these improvements, they occur in 1.9% to 3.7% of patients with ICD over a period of two years. (26,27)

FIGURE 1 Inappropriate shock induced by atrial fibrillation in a patient with a double-chamber implantable cardioverter defibrillator. AS = ATRIAL SENSING, VS = VENTRICULAR SENSING, CD = CARDIOVERSION.
CC202419_3-4_177-85-f1
TABLE 1 Summary of atrial fibrillation history and implantable cardioverter-defibrillator shocks in randomized controlled trials.
RCTNo of ICD
patients
Heart disease
(%)
History of AF (%)EF
(median)
FU (m)
(mean)
ICD shocks (%)
Approp Inapprop
AVID, (13,23)507ICM 81
DICM 19
2132%1839 20
MADIT II (14,21)719ICM 100923%2018 15
DEFINITE (15)229DICM 1002329%2918 21
SCD-HeFT (16,24)811ICM 53
DICM 47
1725%4522 17
MADIT-CRT (17,25)1790ICM 55
DICM 45
1128%3913 7
MADIT-RIT (18)1500ICM 53
DICM 47
1326%1713 4
DANISH (19)556DICM 1002425%6712 6
RCT = randomized controlled trial, No = number, AF = atrial fibrillation, EF = ejection fraction, FU = follow-up, m = months, ICD = implantable cardioverter-defibrillator, approp = appropriate, inapprop = inappropriate, ISM = ischemic cardiomyopathy, NICM = non-ischemic cardiomyopathy.

The second way in which AF may interfere with ICD therapy is direct action of AF in causing an episode of VT/VF, with consequent appropriate shock therapy. An earlier analysis of stored ICD electrograms revealed that approximately 10% of VT episodes were preceded by atrial fibrillation typically associated with a rapid ventricular response. (28) Subsequently, Gronefeld et al. (29) reported that patients in AF experienced appropriate ICD therapy for recurrent ventricular arrhythmias more frequently than those in sinus rhythm (63% vs. 38%, p=0.01) because of a higher incidence of short-long-short cycles preceding ventricular arrhythmias in AF (50% vs. 16%, p=0.002). In the study by Stein et al. (30) which included 537 patients with dual-chamber ICD, 233 (8.6%) of 2602 VT/VF episodes were preceded by a paroxysm of AT or AF. The median duration of these arrhythmias preceding VT/VF was approximately one hour. Ventricular therapies were delivered to treat 205 of these VT/VF episodes, while the remaining 28 episodes terminated spontaneously before an ICD therapy could be delivered. On the other hand, Borleffs et al. reported that patients with permanent AF had higher risk of ventricular arrhythmias triggering ICD discharge compared with those without AF and those with paroxysmal or persistent AF (49% vs. 29%, 26%, and 26%, respectively; p<0.001). (4)

There are several mechanisms that can explain the association between AF and appropriate ICD shocks. First, it is possible that AF and ventricular arrhythmias share risk factors such as ischemia, renal failure, increased sympathetic tone, or increased left ventricular filling pressure, (31,32) which facilitate the initiation of both arrhythmias. Second, in structural heart disease with reduced EF, the rapid ventricular response caused by AF may directly affect ventricular refractoriness and therefore induce ventricular arrhythmia (Figure 2). (30,33) Third, the irregular rhythm of AF results in irregular ventricular activation, creating the short-long-short sequences, which lead to inhomogeneous depolarization and thus to a higher myocardium susceptibility for ventricular arrhythmias. (29)

FIGURE 2 Ventricular tachycardia (VT) induced by rapid ventricular response in patient with permanent atrial fibrillation (AF). Trace A: an acceleration of the ventricular rate in permanent AF. Trace B: the onset of VT with a progressive acceleration of ventricular rate. Traces C and D: established VT with very fast rate (R-R interval of 270 ms). (Adapted from reference (33)).
CC202419_3-4_177-85-f2

Prognostic significance of appropriate and inappropriate implantable cardioverter defibrillator shocks

Two landmark primary prevention ICD studies, MADIT-II (Multicenter Automatic Defibrillation Trial) and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), have found that both appropriate and inappropriate ICD shocks were significant predictors of death, increasing risk of death for appropriate shocks by 3 and 5 times, respectively, and with a 2-fold increase for inappropriate shocks. (21,24,34) In both studies, progressive HF was the leading cause of death among the patients who received at least one ICD shock. (24,34) A meta-analysis by Proietti et al. (35) summarized the existing evidence on the prognostic significance of ICD shocks in patients with HFrEF. In a pooled analysis of almost 200 000 patients with ICD, a significant association was found between ICD shocks and mortality, stronger for appropriate (HR 2.95, p<0.001) than inappropriate shocks (HR 1.71, p<0.001), while the combination of both appropriate and inappropriate shocks was associated with a higher risk of death (HR 4.18, p<0.001) than either type of shock alone.

How we can explain the association between ICD shocks and increased mortality? There are a number of potential mechanisms by which shocks may directly increase the risk of death, such as induced ventricular proarrhythmia, transient myocardial dysfunction, post-shock vasospasm, myocardial stunning, or post-shock pulseless electrical activity, (7,24,36-38) but these mechanisms can potentially be the cause of death within the first 24 hours of a shock. Another explanation arises from the fact that patients with HFrEF and more severe forms of heart disease have an increased tendency to develop ventricular arrhythmias and AF (34,39,40) and consequently a tendency towards a higher incidence of appropriate and inappropriate shocks, (4) which suggests the possibility that ICD shocks are indicator of a higher-risk patient. This explanation is illustrated in the study by Powel et al. (22) who analyzed the rhythms of the first shock delivery in 7 439 randomly-selected patients with an ICD or cardiac resynchronization therapy defibrillator (CRT-D) to determine their relationship with survival. Of the first shock episodes, 58.7% were appropriate shocks for sustained ventricular arrhythmias, and 41.3% were inappropriate shocks for non-ventricular arrhythmias or non-arrhythmic events. Compared with no-shock patients, those who received their first shock for VT/VF or AF/AFL had an increased risk of death (Table 2). In contrast, patients who received an inappropriate shock for ST/SVT or non-arrhythmic events (noise, artifact, and oversensing) had similar survival to those who did not receive a shock. Two important messages emerge from this study: 1) the risk associated with inappropriate shocks is limited to patients receiving shocks for AF/AFL, and 2) increased long-term mortality after shock is more related to the underlying arrhythmia substrate than to an adverse effect from the shock itself. Taking all this together, it is a plausible explanation that the association between ICD shocks and increased mortality is multifactorial, including more advanced heart disease, progression of the underlying arrhythmia substrate, co-morbid conditions, and, to a lesser extent, detrimental effects from the ICD shocks themselves. (22,24,25,41)

TABLE 2 Mortality risk after the first shock in comparison with no shock patients in the ALTITUDE study (22).
Shocked rhythmHazard ratio (95% CL)p value
Ventricular
Monomorphic VT
VF/Polymorphic VT
1.65 (1.36-2.01)
2.10 (1.54-2.86)
<0.0001
<0.0001
Non-ventricular
AF/AFL
ST/SVT
Noise/artefact/oversensing
1.61 (1.17-2.21)
0.97 (0.68-1.37)
0.91 (0.50-1.67)
0.003
0.86
0.76
VT = ventricular tachycardia, VF = ventricular fibrillation, AF= atrial fibrillation, AFL = atrial flutter, ST = sinus tachycardia

Strategies to minimize the interference of atrial fibrillation with implantable cardioverter therapy

According to recent guidelines, the optimization of ICD programming is the initial option to minimize the rate of ICD shocks induced by AF and to improve patient outcomes. (1) This recommendation is based on the results of two meta-analyses, (42,43) which examined the overall effect of ICD therapy reduction programming on several clinical outcomes, including mortality (Table 3). In both meta-analyses, therapy reduction programming was associated with a 50% reduction in inappropriate shocks and with a 30% and 23% reduction in mortality, respectively, compared with the conventional programming. No increase was seen in risk of appropriate shocks or syncope in therapy reduction programming. In line with this recommendation, ICD programming should include: 1) customized bradycardia pacing mode to prevent unnecessary right ventricular pacing in patients without an indication for permanent pacing, (44,45) 2) multi-zone tachycardia detection programming with incorporated prolonged detection time settings and high rate thresholds to avoid unnecessary shocks due to non-sustained VT or clinically stable VT, (46-48) 3) consistent use of algorithms for supraventricular versus ventricular arrhythmias discrimination even for tachycardias with rates up to 230 bpm, (17,26,48) 4) proper atrial sensing for activation of dual-chamber discriminators, (48) 5) systematic use of ATP before shock therapy, also for very fast VT, (46,49,50) and 6) specific algorithms for T-wave discrimination and right ventricular lead noise. (48)

TABLE 3 The effect of therapy reduction versus conventional implantable cardioverter defibrillator programming on clinical outcomes (42).
Clinical outcomeTherapy RP
(n=4089)
Conventional P
(n = 3598)
Hazard ratio
(95% CI)
p value
All-cause mortality207 (5.0%)162 (7.3%)0.70 (0.59-0.84)<0.001
Syncope105 (3.1%)74 (2.5%)1.09 (0.83-1.44)0.5
Appropriate shocks153 (5.2%)137 (5.6%)1.06 (0.75-1.16)0.5
Inappropriate shocks99 (3.4%)168 (6.9%)0.50 (0.39-0.63)<0.001
RP = reduction programming

Pharmacological therapy is the next option for the reduction of ICD shocks caused by AF, (1) but data on this issue are limited. The goal of pharmacological therapy is to slow down the heart rate so that it does not reach the detection zone for VT/VF, or to reduce AF recurrences. In a secondary analysis of the MADIT II study, (51) beta-blocker therapy (metoprolol 44%, carvedilol 42%, atenolol 13%) reduced ICD therapy for VT or VF, but failed to prevent inappropriate shocks induced by AF or SVT. On the other hand, a retrospective analysis of the MADIT-CRT (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) study found that the risk of inappropriate therapy due to AF was significantly reduced in patients receiving carvedilol compared with those who received metoprolol (HR: 0.50, p=0.004). (52) The superior clinical effect of carvedilol versus metoprolol was probably the result of its a larger electrophysiological and pharmacological profile. (53) In a randomized controlled trial on 412 patients with implanted ICD for secondary prevention, (54) a combination of amiodarone and beta-blocker was more effective in the prevention of inappropriate shocks (mostly for supraventricular tachyarrhythmias) than beta-blocker alone (3.3% vs. 15.4%, p=0.006), but with higher rates of adverse thyroid and pulmonary effects and of symptomatic bradycardia. On the other hand, sotalol was not more effective than beta-blockers in reducing risk of inappropriate shocks. Amiodarone can be used for rhythm control after cardioversion, but its success rate in the prevention of AF recurrences in patients with ICD or CRT-D with HFrEF and persistent AF was not higher than 34% at two-year follow-up. (55)

Catheter ablation of the AF or AV junction is recommended in patients with AF-related inappropriate shocks who are unresponsive to pharmacological therapy. (1) Several studies confirmed the feasibility and usefulness of these therapeutic options. (55-58) In 2014, Kosiak et al. (56) published the results of AF catheter ablation in 73 patients with implanted ICD due to ischemic or non-ischemic cardiomyopathy. Complete pulmonary vein isolation (PVI) as the procedural endpoint was achieved in all patients, and re-ablation was necessary in 20 of them. In comparison with the period prior to ablation, there was significant reduction of appropriate and inappropriate shocks after ablation (p=0.03 and p=0.001, respectively). In the study by Miyazaki et al., (57) 14 of 106 ICD patients experienced inappropriate ICD shocks due to AF. PVI was performed in 13 patients, one patient underwent an AVJ ablation because of the absence of an inferior vena, and 4 patients were re-ablated for recurrent AF. After the last ablation procedure, no patients experienced inappropriate shock during the median follow-up of 19 months. In a pooled analysis of 664 patients with CRT-D and permanent AF, (58) patients with AVJ ablation had a significantly lower rate of inappropriate shocks induced by AF and a lower rate of appropriate shocks than those treated with drugs (both p<0.001). These data are important for the treatment of patients with CRT-D, because approximately 26% of this population have AF. (59)

Conclusion

Atrial fibrillation may interfere with ICD therapy in two ways: 1) by inducing inappropriate ICD shock when its rapid ventricular rate reaches a device’s programmed detection zone for VT/VF, and 2) by directly inducing a VT or VF episode with consequent appropriate shock therapy. Patients with ICD who receive appropriate or inappropriate shocks related to AF have a substantially higher risk of death than those who do not receive them. The association between ICD shocks and increased mortality is multifactorial, including more advanced heart disease, progression of the underlying arrhythmia substrate, co-morbid conditions, and, to a lesser extent, detrimental effects from ICD shock itself.

The optimization of ICD programming is the initial option for reducing inappropriate and appropriate shocks induced by AF. Pharmacological therapy with beta-blockers for rate or amiodarone for rhythm control is the next option to this effect. The catheter ablation of AF or AV junction is recommended in patients unresponsive to pharmacological therapy depending on whether it is paroxysmal and persistent AF, or permanent AF.

LITERATURE

1 

Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Developed by the Task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2022;43:3997–4126. https://doi.org/10.1093/eurheartj/ehac262 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/36017572

2 

Giancaterino S, Nishimura M, Birgersdotter-Green U, Hoffmayer KS, Han FT, Raissi F, et al. Clinical factors associated with baseline history of atrial fibrillp, while ation and subsequent clinical outcomes following initial implantable cardioverter-defibrillator placement. Pacing Clin Electrophysiol. 2020;43:542–50. https://doi.org/10.1111/pace.13919 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/32297348

3 

Maruyama M, Yasuoka R, Nagano T, Nakazawa G, Noda T, Nitta T, et al. Impact of atrial fibrillation/flutter on outcomes of patients with implantable cardioverter defibrillators: A sub-analysis of the Nippon Storm study. J Cardiol. 2021 September;78(3):244–9. https://doi.org/10.1016/j.jjcc.2021.04.003 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/33941429

4 

Borleffs CJW, van Rees JB, van Welesenes GH, van de Velde ET, van Erven L, Bax JJ, et al. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:879–85. https://doi.org/10.1016/j.jacc.2009.09.053 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/20185038

5 

Mustafa U, Dherange P, Reddy R, DeVillier J, Chong J, Ihsan A, et al. Atrial fibrillation is associated with higher overall mortality in patients with implantable cardioverter-defibrillator: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7:e010156. https://doi.org/10.1161/JAHA.118.010156 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30554547

6 

van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57:556–62. https://doi.org/10.1016/j.jacc.2010.06.059 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/21272746

7 

Ghezzi ES, Sharman RLS, Selvanayagam JB, Psaltis PJ, Sanders P, Astley JM. Burden of mood symptoms and disorders in implantable cardioverter defibrillator patients: a systematic review and meta-analysis of 39 954 patients. Europace. 2023;25:1–15. https://doi.org/10.1093/europace/euad130 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/37311667

8 

Peinado R, José L, Merino JI. M. Gonzales-Vasserot. Life-threatening implantable defibrillator-induced pro-arrhythmia. Rev Esp Cardiol. 2007;60:770–1. https://doi.org/10.1157/13108282 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/17663861

9 

Dimitri H, John B, Young GD, Sanders P. Fatal outcome from inappropriate defibrillation. Europace. 2007;9:1059–60. https://doi.org/10.1093/europace/eum186 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/17827163

10 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbsch A, Ohm M, et al. Authors/Task Force Members. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34447992

11 

Borne RT, Varosy PD, Masoudi FA. Implantable cardioverter-defibrillator shocks. Epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med. 2013;173:859–65. https://doi.org/10.1001/jamainternmed.2013.428 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23546173

12 

Fleeman BE, Aleong RG. Optimal strategies to reduce inappropriate implantable cardioverter-defibrillator shocks. J Innov Card Rhythm Manag. 2019;10:3623–32. https://doi.org/10.19102/icrm.2019.100403 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/32477727

13 

The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmia. N Engl J Med. 1997;337:1576–83. https://doi.org/10.1056/NEJM199711273372202 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/9411221

14 

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. https://doi.org/10.1056/NEJMoa013474 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/11907286

15 

Kadish A, Dyer A, Daubert JP, Quigg R, Mark Estes NA, Anderson KP, et al. Defibrillator in Non-ischemice Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with noniischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8. https://doi.org/10.1056/NEJMoa033088 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15152060

16 

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Sudden Cardiac Death in Heart Failure Trial. (SCD-HeFT) Investigators. Amiodarone or an implatable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. https://doi.org/10.1056/NEJMoa043399 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15659722

17 

Moss AJ, Hall J, Cannom DS, Klein H, Brown MW, Daubert JP, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329–38. https://doi.org/10.1056/NEJMoa0906431 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/19723701

18 

Moss AJ, Schuger C, Beck ChA, Brown MW, Cannom DS, Daubert JP, et al. MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–83. https://doi.org/10.1056/NEJMoa1211107 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23131066

19 

Køber L, Thune JJ, Nielsen JC, Haarbo J, Korup E, Jensen G, et al. DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375:1221–30. https://doi.org/10.1056/NEJMoa1608029 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27571011

20 

Zweibel S, Cronin EM, Schloss EJ, Auricchio A, Kurita T, Sterns LD, et al. Estimating the incidence of atrial fibrillation in single-chamber implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol. 2019;42:132–8. https://doi.org/10.1111/pace.13555 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30478983

21 

Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wag P, et al. for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II. Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357–65. https://doi.org/10.1016/j.jacc.2007.09.073 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18387436

22 

Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013;62:1674–9. https://doi.org/10.1016/j.jacc.2013.04.083 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23810882

23 

Klein RC, Raitt MH, Wilkoff BL, Beckman KJ, Coromilas J, Wyse G, et al. Analsyis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Cardiovasc Electrophysiol. 2003;14:940–8. https://doi.org/10.1046/j.1540-8167.2003.01554.x PubMed: http://www.ncbi.nlm.nih.gov/pubmed/12950538

24 

Poole JE, Johnson GW, Hellkamp AS, Andersom J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–17. https://doi.org/10.1056/NEJMoa071098 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18768944

25 

Sood N, Ruwald A-CH, Solomon S, Daubert JP, McNitt S, Polonsky B, et al. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. Eur Heart J. 2014;35:106–15. https://doi.org/10.1093/eurheartj/eht451 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24179073

26 

Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zweibel S, et al. On behalf of the PainFree SST Investigators. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. 2015 May;12(5):926–36. https://doi.org/10.1016/j.hrthm.2015.01.017 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25637563

27 

Ruiz-Granell R, Dovellini EV, Dompnier A, Khatighi K, Garcia-Campo E, Olivier A, et al. Algorithm-based reduction of inapropriate defibrillator shock: results of the Inappropriate Shock with PARAD+ Rhythm DiScrimination-Implantable Cardioverter Defibrillator Study. Heart Rhythm. 2019 September;16(9):1429–35. https://doi.org/10.1016/j.hrthm.2019.03.016 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30910709

28 

Marchlinski FE, Callans DJ, Gottlieb ChD, Schwartzman D. MARK Preminger M. Benefits and lessons learned from stored electrogram information in implantable defibrillators. J Cardiovasc Electrophysiol. 1995;6:832–51. https://doi.org/10.1111/j.1540-8167.1995.tb00359.x PubMed: http://www.ncbi.nlm.nih.gov/pubmed/8542079

29 

Grönefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol. 2000;11:1208–14. https://doi.org/10.1046/j.1540-8167.2000.01208.x PubMed: http://www.ncbi.nlm.nih.gov/pubmed/11083241

30 

Stein KM, Euler DE, Mehra R, Seidl K, Slotwiner DJ, Mittal S, et al. Do atrial tachyarrhythmias beget ventricular tachyarrhythmias in defibrillator recipients. J Am Coll Cardiol. 2002;40:335–40. https://doi.org/10.1016/S0735-1097(02)01957-5 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/12106941

31 

Smit MD, Van Dessel PFHM, Rienstra M, Nieuwland W, Wiesfeld ACP, Tan ES, et al. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients. Europace. 2006;8:566–72. https://doi.org/10.1093/europace/eul081 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16864611

32 

Sakhuja R, Shah AJ, Keebler M, Thakur RK. Atrial fibrillation in patients with implantable defibrillators. Cardiol Clin. 2009;27:151–61. https://doi.org/10.1016/j.ccl.2008.09.014 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/19111771

33 

Petrac D, Radićc B, Radeljić V, Hamel D, Filipović J. Impact of atrioventricular node ablation and pacing therapy on clinical course in patients with permanent atrial fibrillation and unstable ventricular tachycardia induced by rapid ventricular response: follow-up study. Croat Med J. 2005 Dec;46(6):929-35. PubMed:https://pubmed.ncbi.nlm.nih.gov/16342346/

34 

Moss AJ, Greenberg H, Case RB, Zareba W, Hall J, Brown MW, et al. Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an Implanted Defibrillator. Circulation. 2004;110:3760–5. https://doi.org/10.1161/01.CIR.0000150390.04704.B7 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15583079

35 

Proietti R, Labos C, Davis M, Thanassoulis G, Santaganeli P, Russo V, et al. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality. Can J Cardiol. 2015;31:270–7. https://doi.org/10.1016/j.cjca.2014.11.023 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25746019

36 

Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Beneditt DG. Sudden death in patients with implantable cardioverter defibrillators. The importance of post-shock electromechanical dissociation. J Am Coll Cardiol. 2002;39:1323–8. https://doi.org/10.1016/S0735-1097(02)01784-9 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/11955850

37 

Clementy N, Bodin A, Bisson A, Teixeira-Gomez AP, Roge S, Angouvlant D, et al. The defibrillation conundrum: new insights into the mechanisms of shock-related myocardial injury sustained from a life-saving therapy. Int J Mol Sci. 2021;22:1–17. https://doi.org/10.3390/ijms22095003 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34066832

38 

Tereshchenko LG, Faddis MN, Fetics BJ, Zelik KE, Efimov IR, Berger RD. Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. J Am Coll Cardiol. 2009;54:822–8. https://doi.org/10.1016/j.jacc.2009.06.004 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/19695461

39 

Tan NY, Roger VL, Killian JM, Cha YM, Noseworthy PA, Dunlay SM. Ventricular arrhythmias among patients with advanced heart failure: a population‐based study. J Am Heart Assoc. 2022;11:e023377. https://doi.org/10.1161/JAHA.121.023377 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34935408

40 

Santhanakrishnan R, Wang NA, Larsen MG, Mgnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133:484–92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26746177

41 

Aktaş MK, Younis A, Zareba W, Kutyifa V, Klein H, Daubert JP, et al. Survival after implantable cardioverter defibrillator shocks. J Am Coll Cardiol. 2021;77:2453–62. https://doi.org/10.1016/j.jacc.2021.03.329 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34016257

42 

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality. A systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:164–70. https://doi.org/10.1161/CIRCEP.113.001217 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24446023

43 

Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: a meta-analysis. Heart Rhythm. 2014;11:828–35. https://doi.org/10.1016/j.hrthm.2014.02.009 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24530622

44 

Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288:3115–23. https://doi.org/10.1001/jama.288.24.3115 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/12495391

45 

Barsheshet A, Moss AJ, McNitt S, Jons C, Glikson M, Klein HU, et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm. 2011;8:212–8. https://doi.org/10.1016/j.hrthm.2010.10.035 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/21044897

46 

Gasparini M, Proclemer A, Klersy C, Kloppe A, Ferrer JBM, Hersi A, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309:1903–11. https://doi.org/10.1001/jama.2013.4598 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23652522

47 

Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014;25:52–9. https://doi.org/10.1111/jce.12273 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24112717

48 

Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace. 2016;18:159–83. https://doi.org/10.1093/europace/euv411 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26585598

49 

Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicentre EMPIRIC trial. J Am Coll Cardiol. 2006;48:330–9. https://doi.org/10.1016/j.jacc.2006.03.037 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16843184

50 

Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591–6. https://doi.org/10.1161/01.CIR.0000145610.64014.E4 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15492306

51 

Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, et al. Effects of Beta-Blockers on Implantable Cardioverter Defibrillator Therapy and Survival in the Patients with Ischemic Cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96:691–5. https://doi.org/10.1016/j.amjcard.2005.04.046 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16125497

52 

Ruwald MH, Abu-Zeitone A, Jons C, Ruwald AC, McNitt S, Kutyifa V, et al. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2013;62:1343–50. https://doi.org/10.1016/j.jacc.2013.03.087 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23770172

53 

Metra M, Giubbini R, Nodari S, Boldi E, Moden MG, Dei CASL. Differential Effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546–51. https://doi.org/10.1161/01.CIR.102.5.546 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/10920067

54 

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165–71. https://doi.org/10.1001/jama.295.2.165 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16403928

55 

Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi Ch, Lakkireddy D, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device. Results from the AATAC multicenter randomized trial. Circulation. 2016;133:1637–44. https://doi.org/10.1161/CIRCULATIONAHA.115.019406 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27029350

56 

Kosiuk J, Nedios S, Darma A, Rolf S, Richter S, Arya A, et al. Impact of single atrial fibrillation catheter ablation on implantable cardioverter defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2014;16:1322–6. https://doi.org/10.1093/europace/euu018 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24532559

57 

Miyazaki S, Taniguchi H, Kusa S, Komatsu Y, Ichihara N, Takagi T, et al. Catheter ablation of atrial tachyarrhythmias causing inappropriate implantable cardioverter-defibrillator shocks. Europace. 2015;17:289–94. https://doi.org/10.1093/europace/euu185 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25061229

58 

Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, et al. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations: atrioventricular junction ablation in CRT patients with AF. Eur J Heart Fail. 2018;20:1472–81. https://doi.org/10.1002/ejhf.1117 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/29251799

59 

Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt A, et al. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11088 patients - who is doing what to whom and how? Eur J Heart Fail. 2018;20:1039–51. https://doi.org/10.1002/ejhf.1142 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/29457358


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.